Elixir Medical Corporation

Heading to #ESC2024? Join us as we announce late-breaking, one-year primary outcomes from the 2,400-patient INFINITY-SWEDEHEART clinical trial evaluating #DynamX Coronary Bioadaptor System compared to contemporary DES.    The results will be presented by Dr. David Erlinge in a Hot Line session  on Monday, September 2, 2024.    Stefan James   Read more here: https://lnkd.in/eJnVhvd4   #Medtech #Innovation #Cardiology   CE marked. Not for sale in the U.S.    PMN 1895 REV A

Simultaneous publication in The Lancet of the late-breaking RCT clinical data demonstrating significant benefit of the DynamX® Coronary Bioadaptor System compared to contemporary drug-eluting stent for target lesion failure in complex patient population subsets from the 2400 patients INFINITY-SWEDEHEART RCT. The data included an analysis of patients with acute coronary syndrome (ACS), small vessel lesions, and lesions within the left anterior descending (LAD) artery. #TCT2024

📊NEW DATA: INFINITY-SWEDEHEART RCT 12-month outcomes comparing #DynamX®* with a contemporary DES in patients with acute coronary syndrome and complex lesion subsets after six months. ➡️ Landmark analysis (6-12 months) showed DynamX bioadaptor significantly reduces adverse events compared to DES, confirming unique mechanism of action after unlocking at 6 months ➡️ Clinical results in patients with ACS demonstrated 83% reduction (0.3% vs. 1.8%; (p<0.018)) in TLF rate ➡️ Clinical results in patients with lesions in the LAD vessels demonstrated 73% reduction (0.2% vs. 2.2%) in TLF rate ➡️ There were no TLF events in patients with small vessels (less than or equal to 2.75 mm) in the DynamX arm Learn more about the results: https://lnkd.in/etMwb9XZ INFINITY-SWEDEHEART data were published concurrently in The Lancet: https://lnkd.in/etYST6ap *CE marked. Not for sale in the U.S. #Cardiovascular #Medtech #Innovation #TCT2024 PMN 2032 REV A

🗓️ Mark your calendar! We’ll be sharing new clinical data on two transformative platforms at #TCT2024! ✔️ #DynamX* bioadaptor - We’ll share late-breaking data from ACS population and complex lesion subsets in the INFINITY-SWEDEHEART RCT, a large (2,400-patient) randomized trial in a representative patient population including evaluating the use of the #bioadaptor in more complex clinical setting ✔️ #LithiX** - We’ll share full six-month & OCT imaging sub-study data from our PINNACLE I Trial evaluating the safety and effectiveness of this novel Hertz contact lithotripsy system over a broad range of calcium morphologies Learn more about our full session line up and visit us at booth #2823: https://lnkd.in/dKFSaPfu   *DynamX is CE marked. Not approved in the U.S.   **LithiX is not approved in the U.S.   #MedTech #Innovation #TCT #cardiovascular #hearthealth   PMN 2022 Rev A

Join us at #OptimaLondon2024 in London on October 7– 8, 2024.   Don't miss #DynamX® Bioadaptor at “Innovation Alley” featuring expert physician insights from Drs. Colm Hanratty, Rasha Al-Lamee, Jonathan Hill, Angela McInerney.   Come learn more and interact with our innovative technology!    Optima Education Ltd James Spratt.    CE marked. Not for sale in the U.S.   #MedTech #Innovation    PMN 2034 Rev A

Hear from Dr. Chin Chee Yang, from the National Heart Center in Singapore, as he shares his experience with the #DynamX® bioadaptor and the patients he thinks may benefit the most from the technology. BIOADAPTOR RCT data and the bioadaptor’s unique mechanism of action were recently validated further with results from the 2,400-patient INFINITY-SWEDEHEART trial which showed consistency of low and plateauing adverse event rates after the unlocking of the bioadaptor at six months.   Watch the full video here: https://lnkd.in/e3fak4qw    CE marked. Not for sale in the U.S.    #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1979 REV B

Next up in our #DynamX® expert user interview series, Dr. Nikos Werner from the Heart Center in Trier, Germany, discusses his view on the bioadaptor’s unique mechanism of action. This feature was further validated by recently presented INFINITY SWEDEHEART data.    Watch the full video here: https://lnkd.in/e-gpCqJh    CE marked. Not for sale in the U.S.   #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1983 REV B

Don’t miss Dr. Johan Bennett from UZ Leuven in Belgium as he shares his perspective on the BIOADAPTOR RCT two-year data and his observations on the impact the #DynamX® bioadaptor has on patient outcomes. Dr. Bennett predicted further validation of the bioadaptor benefits, including its unique mechanism of action, through the INFINITY-SWEDEHEART trial - a study that ultimately showed significantly reduced adverse events compared to DES at six months after bioadaptor unlocked. Watch the full video here: https://lnkd.in/eP68F9v3    CE marked. Not for sale in the U.S.   #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1985 REV B

Dr. Ing Haan Lim, from Mount Elizabeth Medical Centre in Singapore, shares the key reasons she chooses to use #DynamX® bioadaptor with her patients.    Watch the full video here: https://lnkd.in/e75EvhFW    CE marked. Not for sale in the U.S.   #Cardiovascular #Medtech #Innovation #leavetherightthingbehind   PMN 1981 REV A

Attending EuroCTO Club? Don't miss #DynamX® Bioadaptor LIVE CASE with Dr. Omer Goktekin. We hope to see you at our booth! CE marked. Not for sale in the U.S. #MedTech #Innovation #CCT #CTO PMN 2018 Rev A